Early-Stage Triple-Negative Breast Cancer Treatment

Authored by Eric Kowalchyk, published on 2026-09-03 19:06:25.0

  1. Confirm ER/PR <1%, HER2-Negative Disease And Determine cT/cN
    • Stratify Nonmetastatic TNBC By Clinical Tumor And Nodal Stage
      • Complete Baseline Labs, Echocardiogram and Obtain Germline BRCA1/2 Testing
        • cT1c N0
          • Give neoadjuvant anthracycline/taxane-based chemotherapy
            • Perform Breast Surgery And Axillary Staging After Neoadjuvant Therapy
              • If Pembrolizumab Was Started Neoadjuvantly, Resume Adjuvant Pembrolizumab After Surgery
                • Assess pathologic response. Residual Invasive Disease In Breast Or Nodes?
                  • If Started Neoadjuvantly, Continue Adjuvant Pembrolizumab + Assess Additional Post-Neoadjuvant Therapy
                    • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                      • Perform Exams Every 3–6 Months Initially And Annual Mammography
                    • Adjuvant capecitabine when appropriate
                      • Deliver RT if indicated*
                        *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                        • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                          • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                            • Perform Exams Every 3–6 Months Initially And Annual Mammography
                          • Perform Exams Every 3–6 Months Initially And Annual Mammography
                  • pCR → If Started Neoadjuvantly, Continue Adjuvant Pembrolizumab to Complete KEYNOTE-522 Course
                    • Deliver RT if indicated*
                      *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                      • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                        • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                          • Perform Exams Every 3–6 Months Initially And Annual Mammography
                        • Perform Exams Every 3–6 Months Initially And Annual Mammography
        • cT1a–b N0
          • Perform Breast Surgery And Axillary Staging First
            • Stratify By Pathologic Tumor Size And Nodal Status
              • Omit Adjuvant Chemotherapy For pT1a N0 TNBC
                • Deliver RT if indicated*
                  *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                  • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                    • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                      • Perform Exams Every 3–6 Months Initially And Annual Mammography
                    • Perform Exams Every 3–6 Months Initially And Annual Mammography
              • Shared Decision: Omit Chemotherapy Or Give TC Q3W ×4 For pT1b N0
                • Deliver RT if indicated*
                  *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                  • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                    • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                      • Perform Exams Every 3–6 Months Initially And Annual Mammography
                    • Perform Exams Every 3–6 Months Initially And Annual Mammography
              • Give TC Q3W ×4; Use AC-T For Higher-Risk pT1c N0 Disease
                • Deliver RT if indicated*
                  *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                  • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                    • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                      • Perform Exams Every 3–6 Months Initially And Annual Mammography
                    • Perform Exams Every 3–6 Months Initially And Annual Mammography
              • Give Adjuvant AC-T; Do Not Initiate Pembrolizumab After Surgery
                • Deliver RT if indicated*
                  *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                  • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                    • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                      • Perform Exams Every 3–6 Months Initially And Annual Mammography
                    • Perform Exams Every 3–6 Months Initially And Annual Mammography
        • cT1c N+ or cT2–4 N0/N+ (Stage II–III)
          • Pembrolizumab contraindicated or inappropriate?
            • Give Paclitaxel/Carboplatin ×4 Then AC/EC ×4 Without Pembrolizumab
              • Perform Breast Surgery And Axillary Staging After Neoadjuvant Therapy
                • If Pembrolizumab Was Started Neoadjuvantly, Resume Adjuvant Pembrolizumab After Surgery
                  • Assess pathologic response. Residual Invasive Disease In Breast Or Nodes?
                    • If Started Neoadjuvantly, Continue Adjuvant Pembrolizumab + Assess Additional Post-Neoadjuvant Therapy
                      • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                        • Perform Exams Every 3–6 Months Initially And Annual Mammography
                      • Adjuvant capecitabine when appropriate
                        • Deliver RT if indicated*
                          *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                          • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                            • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                              • Perform Exams Every 3–6 Months Initially And Annual Mammography
                            • Perform Exams Every 3–6 Months Initially And Annual Mammography
                    • pCR → If Started Neoadjuvantly, Continue Adjuvant Pembrolizumab to Complete KEYNOTE-522 Course
                      • Deliver RT if indicated*
                        *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                        • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                          • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                            • Perform Exams Every 3–6 Months Initially And Annual Mammography
                          • Perform Exams Every 3–6 Months Initially And Annual Mammography
            • Give Pembrolizumab 200 mg Q3W With Paclitaxel/Carboplatin ×4, Then AC/EC ×4
              • Check CBC, CMP, And TSH Each Cycle; Hold Pembrolizumab For Significant Immune Toxicity
                • Perform Breast Surgery And Axillary Staging After Neoadjuvant Therapy
                  • If Pembrolizumab Was Started Neoadjuvantly, Resume Adjuvant Pembrolizumab After Surgery
                    • Assess pathologic response. Residual Invasive Disease In Breast Or Nodes?
                      • If Started Neoadjuvantly, Continue Adjuvant Pembrolizumab + Assess Additional Post-Neoadjuvant Therapy
                        • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                          • Perform Exams Every 3–6 Months Initially And Annual Mammography
                        • Adjuvant capecitabine when appropriate
                          • Deliver RT if indicated*
                            *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                            • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                              • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                                • Perform Exams Every 3–6 Months Initially And Annual Mammography
                              • Perform Exams Every 3–6 Months Initially And Annual Mammography
                      • pCR → If Started Neoadjuvantly, Continue Adjuvant Pembrolizumab to Complete KEYNOTE-522 Course
                        • Deliver RT if indicated*
                          *adjuvant pembrolizumab may be administered concurrently with RT or after RT
                          • Meets OlympiA Criteria: gBRCA1/2 Pathogenic Variant + pT2+ or ≥pN1?
                            • If OlympiA Eligible, Give Olaparib 300 mg BID × 1 Year
                              • Perform Exams Every 3–6 Months Initially And Annual Mammography
                            • Perform Exams Every 3–6 Months Initially And Annual Mammography
  2. Capecitabine Benefit With Ongoing Pembrolizumab Is Uncertain; Individualize Sequencing And Toxicity Monitoring
    CREATE-X established capecitabine after residual TNBC without perioperative immunotherapy. KEYNOTE-522 did not establish the efficacy of adding capecitabine to adjuvant pembrolizumab.
tosprivacy